^
Association details:
| Biomarker: | TNFSF4 overexpression + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer
Published date:
08/08/2023
Excerpt:
We collected baseline formalin fixed and paraffin embedded (FFPE) tumor samples from a multi-institutional cohort of 144 high PD-L1 expressing (TPS≥50%) NSCLC patients treated with front-line pembrolizumab in 10 institutions between 2017-2022….Finally, using the Q3 cutpoint of OX40L expression, we confirmed that patients with high OX40L expression in the tumor compartment had longer PFS in the discovery (p=0.046) and the validation sets (p=0.016).
